Company: NDRA
Filing Date: 2025-07-09
Form Type: S-1
Source: 0001654954-25-007870
Chunk: 2

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-07-09
Form: S-1
Chunk 2
---
000 shares of common stock, par value $0.0001 per share (“common stock”).

We are also offering pre-funded warrants to purchase up to an aggregate of 15,700,000 shares of common stock (the “Pre-Funded Warrants”), in lieu of shares of common stock to those purchasers whose purchase of shares of common stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding shares of common stock following the consummation of this offering. A holder of Pre-Funded Warrants will not have the right to exercise any portion of its Pre-Funded Warrants if the holder, together with its affiliates and certain related parties, would beneficially own in excess of 4.99% (or, at the election of the holder, 9.99%) of the number of shares of common stock outstanding immediately after giving effect to such exercise. Each Pre-Funded Warrants is exercisable for one share of our common stock. For each Pre-Funded Warrant that we sell, the number of shares of common stock that we are selling will be decreased on a one-for-one basis. The public offering price of each Pre-Funded Warrant will be equal to the price being sold to the public in this offering, minus $0.0001. The Pre-Funded Warrants are immediately exercisable, subject to the beneficial ownership limitations described above, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. This prospectus also relates to the offering of common stock issuable upon exercise of the Pre-Funded Warrants. We collectively refer to the shares of common stock and Pre-Funded Warrants offered hereby and the shares of common stock underlying the Pre-Funded Warrants as the “securities.” There is no established public trading market for the Pre-Funded Warrants, and we do not expect a market to develop. We do not intend to apply for listing of the Pre-Funded Warrants on any securities exchange or other nationally recognized trading system. Without an active trading market, the liquidity of the Pre-Funded Warrants will be limited.

Our common stock trades on the Nasdaq Capital Market under the symbol “NDRA.” The assumed public offering price for each share of common stock or Pre-Funded Warrant for purposes of this preliminary prospectus is $8.30 (equal to